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StevenseJohnson syndrome (SJS) is an acute inﬂammatory vesiculobullous reaction of the skin and
mucosa, such as the ocular surface, oral cavity, and genitals. In patients with extensive skin detachment
and a poor prognosis, the condition is called toxic epidermal necrolysis (TEN). Severe ocular complica-
tions (SOCs) appear in somedbut not alldSJS/TEN patients who are diagnosed by dermatologists, and
cold medicines including multi-ingredient cold medications and nonsteroidal anti-inﬂammatory drugs
are the main causative drugs particularly for SJS/TEN with SOCs and all SJS and TEN. In this review, we
focus on the genetic predisposition of cold medicine-related SJS/TEN (CM-SJS/TEN) with SOCs. CM-SJS/
TEN with SOCs was strongly associated with HLA-A*02:06 and signiﬁcantly associated with HLA-
B*44:03 in Japanese individuals, signiﬁcantly associated with HLA-B*44:03 in Indian and Brazilian in-
dividuals, and associated with HLA-A*02:06 in Korean individuals. In the ﬁrst genome-wide association
study (GWAS), we found an association between the prostaglandin E receptor 3 (PTGER3) gene and SJS/
TEN with SOCs. In this study, we focused on CM-SJS/TEN with SOCs and found that the association of CM-
SJS/TEN with SOCs became stronger than all SJS/TEN with SOCs. In the second GWAS, we found an as-
sociation between the IKZF1 gene and CM-SJS/TEN with SOCs not only in Japanese, but also in Korean and
Indian populations. Moreover, we found that TSHZ2 gene single nucleotide polymorphisms (SNPs) also
showed especially low p values in the Japanese population; however, this association was not found in
the Korean population. Furthermore, we investigated the interaction between susceptibility genes, and
found multiplicative interactions of HLA-A*02:06 and TLR3 SNPs and additive interactions of HLA-A*02:06
and PTGER3 SNPs.
Copyright © 2016, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. StevenseJohnson syndrome/toxic epidermal necrolysis in
ophthalmology
StevenseJohnson syndrome (SJS) is an acute inﬂammatory
vesiculobullous reaction of the skin and mucosa, such as the ocular
surface, oral cavity, and genitals. In patients with extensive skin
detachment and a poor prognosis, the condition is called toxic
epidermal necrolysis (TEN). Table 1 shows the diagnostic criteria for
SJS and TEN in Japan.1 A deﬁnite diagnosis of SJS requires mucosal
lesions, whereas a deﬁnite diagnosis of TEN does not. Thus, SJS/TENinterest to declare.
dical Science and Technology
dicine, 465 Kajiicho, Hirokoji,
iety of Taiwan. Published by Elseviwith mucosal lesions consists of SJS and a part of TEN. Moreover,
not all cases of SJS/TEN with mucosal lesions have severe ocular
lesions such as severe conjunctivitis with pseudomembrane and
ocular surface epithelial defects in the acute stage (Figure 1).
Figure 2 shows a case of severe conjunctivitis with pseudomem-
brane and ocular surface epithelial defects in the acute stage. It is
reported that about 40% of SJS/TEN cases had severe ocular com-
plications (SOCs) with pseudomembrane and ocular surface
epithelial defects.1
Furthermore, dermatologists see SJS/TEN patients only in their
acute stage, whereas ophthalmologists encounter such patients not
only in the acute stage but also in the chronic stage. Therefore, for
ophthalmologists, it is not easy to render a differential diagnosis of
SJS or TEN when patients present in the chronic stage because the
vesiculobullous skin lesions expressed in the acute stage have
healed by the chronic stage.2 Diagnosis of SJS/TEN iner Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
Table 1
Diagnostic criteria for StevenseJohnson syndrome and toxic epidermal necrolysis by Japanese Ministry of Health, Labour, and Welfare (2005).
Diagnostic criteria
StevenseJohnson syndrome
Clinical entity
A severe mucocutaneous disorder characterized by erythema, epidermal detachment, and enanthema accompanied by high fever
Essential criteria (required)
1. Severe hyperemic and/or hemorrhagic mucocutaneous lesions
2. Epidermal detachment involving <10% of the total body surface area
3. High-grade fever (>38.0C) in the absence of antipyretic therapy
Supportive ﬁndings
1. Flat, atypical target lesions
2. Bilateral acute keratoconjunctivitis accompanied by ocular surface epithelial defect and/or pseudomembrane formation
3. Histologic evidence of epidermal necrosis
Diagnostic criteria
Toxic epidermal necrolysis
Clinical entity
A severe mucocutaneous disorder characterized by extensive erythema, epidermal detachment (including blisters and erosions), and enanthema accompanied by high
fever. The extent of epidermal detachment is >10% of the total body surface area
Essential criteria (required)
1. Epidermal detachment involving >10% of the total body surface area
2. Exclusion of staphylococcal scalded skin syndrome
3. High-grade fever (>38.0C) in the absence of antipyretic therapy
Supportive ﬁndings
1. Generalized macular or diffuse erythema
2. Enanthema including bilateral acute keratoconjunctivitis accompanied by ocular surface epithelial defect and/or pseudomembrane formation
3. Histologic evidence of marked epidermal necrosis
Note. From “Predictive factors associated with acute ocular involvement in StevenseJohnson syndrome and toxic epidermal necrolysis,” C. Sotozono, M. Ueta, E. Nakatani, A.
Kitami, H. Watanabe, H. Sueki, et al., 2015, Am J Ophthalmol, 160, p. 228e37 e2. Copyright 2015, Elsevier Science. Reproduced with permission.
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high fever, serious mucocutaneous illness with skin eruptions,
and involvement of at least two mucosal sites including the ocular
surface.3e14 SJS/TEN patients with SOC in the acute stage often
experience severe ocular sequelae, such as vision loss and very
severe dry eye for which these patients would not have been able to
lead a normal life.15 Figure 3 shows severe ocular sequelae such asFigure 1. Ophthalmologists often report both SJS and TEN with severe ocular complica-
tionsas SJS. SJS¼ StevenseJohnson syndrome;TEN¼ toxicepidermalnecrolysis.Note. From
Ueta M. Genetic predisposition to StevenseJohnson syndrome with severe ocular surface
complications. Cornea. 2015;34(Suppl. 11):S158eS165. Reproduced with permission.very severe dry eye, trichiasis, symbrepharon, scarring of lid con-
junctiva, and conjunctival invasion of the cornea in the chronic
stage. We deﬁned patients with SOCs in the acute stage as those
who manifested pseudomembranes and epithelial defects on the
ocular surface (cornea and/or conjunctiva),16 and in the chronic
stage as patients with ocular sequelae such as severe dry eye,
trichiasis, symblepharon, and conjunctival invasion into the
cornea.15 Thus, ophthalmologists tend to report both SJS and TEN
with SOCs as “SJS” in a broad sense.2
To summarize, SOCs appear in somedbut not alldSJS/TEN pa-
tients who are diagnosed by dermatologists.2. Causative drug and human leukocyte antigen analysis
SJS/TENs are rare with an annual incidence rate of 1e6 cases/1
million persons,1,17,18 but SJS/TEN carry high mortality rates of 3%
for SJS and 27% for TEN.19 Moreover, they often associated with
inciting drugs.3e5,10,18,20e22 It was reported that allopurinol and
anticonvulsants such as carbamazepine are the main inciting drugs
for SJS/TEN23; however, we2e5,10 and others20,22 found that cold
medicines including multi-ingredient cold medications and
nonsteroidal anti-inﬂammatory drugs (NSAIDs) are also major
causative drugs for SJS/TEN.
Furthermore, the association between human leukocyte antigen
(HLA) genotypes and drug-induced severe cutaneous adverse re-
actions (SCARs) including SJS/TEN has been reported.
Carbamazepine-induced SJS/TEN exhibited a very strong associa-
tion with the HLA-B*15:02 allele [case n ¼ 44, control (tolerant)
n ¼ 101, odds ratio (OR) ¼ 2504, pcorrected ¼ 3.1  1027] in
Taiwanese Han Chinese patients.24 The HLA-A*31:01 allele was also
reported to be strongly associated with carbamazepine-induced
SCAR including SJS/TEN and drug-induced hypersensitivity syn-
drome (DIHS) in Japanese [case n ¼ 77, control (tolerant) n ¼ 420,
OR¼ 9.5, p¼ 1.1 1016]25 and European individuals [case n¼ 145,
control (normal) n ¼ 257, OR ¼ 15.0, p ¼ 3.5  108],26 suggesting
that different ethnic groups may have the different risk factors for
carbamazepine-induced SCARs. Allopurinol, a uric acid-lowering
drug, could also induce SCAR including SJS, TEN, and DIHS, and
Figure 2. Severe conjunctivitis with pseudomembrane and ocular surface epithelial defects in the acute stage of StevenseJohnson syndrome (SJS). Reproduced from Ueta with
permission from Medical-Aoi Publications, Inc.
Figure 3. Severe ocular sequelae such as very severe dry eye, trichiasis, symbrepharon, scarring of lid conjunctiva and conjunctival invasion of cornea in the chronic stage of
StevenseJohnson syndrome (SJS). Reproduced from Ueta with permission from Medical-Aoi Publications, Inc.
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58:01 in Han Chinese [case n ¼ 51, control (tolerant) n ¼ 135,
OR¼ 580, pcorrected ¼ 4.7 1024],27 Caucasian [case n¼ 27, control
(normal) n ¼ 1822, OR ¼ 80, pcorrected <106],28 and Japanese pa-
tients (case n ¼36, control (normal) n ¼ 986, OR ¼ 62.8,
p ¼ 5.4  1012),29 suggesting that different ethnic groups may
share the same risk factors for allopurinol-induced SCARs.
We have also reported that cold medicine-related SJS/TEN (CM-
SJS/TEN) with SOCs was strongly associated with HLA-A*02:06 [case
n ¼ 151, control (normal) n ¼ 639, OR ¼ 5.6, p ¼ 2.7  1020] and
signiﬁcantly associated with HLA-B*44:03 in Japanese individuals
[case n ¼ 151, control (normal) n ¼ 639, OR ¼ 2.0, p ¼ 1.3  103],
and these HLA genotypes were irrelevant to CM-SJS/TEN without
SOCs.3 Thus, genetic predisposition such as HLA genotype might be
different between SJS/TENwith and without SOCs.3 Moreover, HLA-
A*02:06 and HLA-B*44:03 are not associated with cold medicine
unrelated (other medicine related) SJS/TEN with SOCs,3 suggesting
that genetic predisposition, such as HLA genotype, might be
different depending on their causative drugs.3,5,30,31Figure 4. Associations between HLA type and the main causative drugs of SJS/TEN. HLA ¼ hu
seJohnson syndrome; TEN ¼ toxic epidermal necrolysis. Note. From “IKZF1, a new susceptibili
with severe mucosal involvement,” by M. Ueta, H. Sawai, C. Sotozono C, et al., 2015, J Allergy CWe also reported that CM-SJS/TEN with SOCs was signiﬁcantly
associated with HLA-B*44:03 in Indian [case n ¼ 20, control
(normal) n¼ 55, OR¼ 12.3, p¼ 1.1 105] and Brazilian [especially
Brazilian Caucasians; case n¼ 15, control (normal) n¼ 62, OR¼ 6.2,
p ¼ 3.7  103] individuals, and that HLA-A*02:06 was associated
with CM-SJS/TEN with SOC in Korean individuals [case n ¼ 31,
control (normal) n ¼ 90, OR ¼ 3.0, p ¼ 0.018].4
We have likewise reported that cold medicines including multi-
ingredient cold medications and NSAIDs were the main causative
drugs for SJS/TEN with SOCs in all SJS and TEN.1e3,5,10,31 About 80%
of our SJS/TEN with SOC patients have developed SJS/TEN within
several days after receiving treatment for common cold.2,10
Interestingly, allopurinol might induce SJS/TEN without
SOCs,30 and not all cases of carbamazepine-induced SJS/TEN have
SOCs.2
In summary, genetic predisposition, such as HLA genotype,
might be different depending on the causative drugs and their
phenotype, for example, with and without SOCs (Figure 4).2,3,5,31man leukocyte antigen; NSAIDs ¼ nonsteroidal anti-inﬂammatory drugs; SJS ¼ Steven-
ty gene for cold medicine-related StevenseJohnson syndrome/toxic epidermal necrolysis
lin Immunol, 135, p. 1538e1545. Copyright 2015,Mosby. Reproduced with permission.
Figure 5. 20 SNPs of PTGER3 associated with SJS/TEN with severe ocular complication. PTGER3 ¼ prostaglandin E receptor 3; SJS ¼ StevenseJohnson syndrome; SNP ¼ single
nucleotide polymorphism; TEN ¼ toxic epidermal necrolysis. Note. From “Epistatic interaction between Toll-like receptor 3 (TLR3) and prostaglandin E receptor 3 (PTGER3) genes,” by
M. Ueta, G. Tamiya, K. Tokunaga, et al., 2012, J Allergy Clin Immunol, 129, p. 1413e1416. Copyright 2012, Mosby. Reproduced with permission.
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3.1. PTGER3: ﬁrst genome-wide association study
We previously reported that a genome-wide association study
(GWAS) using the Affymetrix GeneChip Mapping 500K Array Set
(Affymetrix, Santa Clara, Calif) showed an association between
prostaglandin E receptor 3 (PTGER3) gene and SJS/TEN with SOCs.10
Moreover, we analyzed a total of 38 single nucleotide poly-
morphisms (SNPs) of the PTGER3 gene using DigiTag2 assay32,33 and
found 20 SNPs associated with SJS/TEN with SOCs (Figure 5).34 The
protein of PTGER3 gene is EP3. EP3 is one of the four receptors (EP1,
EP2, EP3 and EP4) of prostaglandin E2 (PGE2).35
Cold medicine such as NSAIDs (e.g., ibuprofen and loxoprofen)
and cold medicine ingredients (e.g., acetaminophen) have the
suppressive effect in the production of prostanoid, including PGE
(Figure 6).35Figure 6. Cold medicine such as nonsteroidal anti-inﬂammatory drugs (NSAIDs) and col
including PGE2.It was reported that PGE2 acts at EP3 in the airway epithelium
and negatively regulates inﬂammation in the mouse asthma
model.36 We also reported that EP3 negatively regulated the
inﬂammation of ocular surface in the mouse allergy conjuncti-
vitis model37 and skin in the mouse contact dermatitis model.38
Because PGE2 acts at EP3 and negatively regulates mucocuta-
neous inﬂammation,36e38 we suggest that the suppression of
PGE2 production by cold medicine might contribute to the onset
and pathogenesis of CM-SJS/TEN with SOCs.2,10 Therefore, we
turned to CM-SJS/TEN with SOCs. When we focused on CM-SJS/
TEN with SOCs, the association with PTGER3 gene became
stronger than that in total SJS/TEN with SOCs; seven of 18 SNPs
already reported to be associated with SJS/TEN were signiﬁcantly
associated with CM-SJS/TEN with SOCs after Bonferroni correc-
tion.14 PTGER3 SNP rs1327464 (G vs. A) was most signiﬁcantly
associated with CM-SJS/TEN with SOCs; the OR for the major
allele was 0.232 (p ¼ 7.92  1010).14 Figure 7 shows the p valuesd medicine ingredients have the suppressive effect of the production of prostanoid,
Figure 7. PTGER3 SNPs associated with CM-SJS/TEN with SOCs. PTGER3 SNP rs1327464 was most signiﬁcantly associated with CM-SJS/TEN with SOCs
Figure 8. Downregulation of EP3 in the conjunctival epithelium of SJS/TEN with severe ocular complications. EP3 (brown stain) is strongly downregulated in the conjunctival
epithelium of SJS compared with chemical burns. Controls consisted of isotype control antibodies instead of anti-EP3 antibodies. SJS ¼ StevenseJohnson syndrome; TEN ¼ toxic
epidermal necrolysis. Note. From “Prostaglandin E receptor subtype EP3 expression in human conjunctival epithelium and its changes in various ocular surface disorders,” by M.
Ueta, C. Sotozono, N. Yokoi, T. Inatomi, S. Kinoshita, 2011, PLoS One, 6, p. e25209. Copyright 2011, Public Library of Science. Reproduced with permission.
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(GG vs. GA þ AA); p ¼ 1.90  108, OR ¼ 0.223.14
We also previously reported that EP3 protein levels are much
lower in the conjunctival epithelium of patients with SJS/TEN with
SOCs than control individuals such as conjunctival chalasis patients
and chemical burn patients (Figure 8).39 Thus, EP3 expression
might be downregulated in the ocular surface of the SJS/TEN with
SOCs patients.
Furthermore, because patients with CM-SJS/TEN with SOCs
have developed this condition by taking cold medicines after
having a common cold as a result of some viral or mycoplasma
infections, we assume that not only cold medicine, but also some
microbial infectious such as virus or mycoplasma, might be
important and necessary to trigger the onset of SJS/TEN with
SOCs.2,31
3.2. IKZF1: second GWAS
In the second GWAS, we focused on CM-SJS/TEN with SOCs, and
performed a GWAS of Japanese 117 cases and 691 controls using the
Affymetrix AXIOM Genome-Wide ASI 1 Array (Affymetrix, Santa
Clara, Calif).5 The Manhattan plot of the GWAS indicated that the
HLA-A region showed the strongest association with susceptibility
to CM-SJS/TEN with SOCs (Figure 9),5 which was consistent with
ﬁndings from our previous studies.3,11,12
Outside of the HLA region, there were 60 SNPs with p < 103 (in
the allele frequency, dominant model, or recessive model) in the
GWAS.5 Of the 60 SNPs, 47 were p < 104, and 11 of these 47 were
p < 105.5 Among the 11 SNPs of eight genes that were p < 105,
IKZF1 showed especially low p values [rs897693: (C vs. T) OR ¼ 4.3,
p ¼ 1.2  107; (CC þ CT vs. TT), OR ¼ 5.0, p ¼ 2.1  108].5
Moreover, we genotyped the SNPs of the IKZF1 gene with all
Japanese samples (149 SJS, 877 controls) with 16 additional Japa-
nese cases, Korean samples (31 SJS and 90 controls), Indian samples
(20 CM-SJS/TEN with SOCs and 56 controls), and Brazilian samples
(39 CM-SJS/TEN with SOCs and 135 controls), and then found that aFigure 9. Manhattan plot of a genome-wide association study using the Affymetrix AXIOM
susceptibility gene for cold medicine-related StevenseJohnson syndrome/toxic epidermal n
2015, J Allergy Clin Immunol, 135, p. 1538e1545. Copyright 2015, Mosby. Reproduced with pmeta-analysis from the Japanese, Korean, Indian, and Brazilian
samples showed a signiﬁcant genome-wide association between
CM-SJS/TEN with SOCs and IKZF1 [rs4917014 (G vs. T), OR ¼ 0.5,
p¼ 8.5 1011].5 These ﬁndings show that IKZF1may be a universal
marker for susceptibility to CM-SJS/TEN with SOCs.5
Furthermore, we have performed a functional analysis for SNPs
of the IKZF1 gene and found that the Ik2/Ik1 (both are splicing
isoforms) ratio may be inﬂuenced by IKZF1 SNPs that are signiﬁ-
cantly associated with susceptibility to CM-SJS/TEN with SOCs.5 To
elucidate the role of IKZF1 in the pathogenesis of CM-SJS/TEN with
SOCs, we are going to do further investigations.
3.3. TSHZ2: second GWAS
Among the 11 SNPs of eight genes that were p < 105 in the
second GWAS, TSHZ2 also showed especially low p values
[rs4809905: (A vs. G), OR ¼ 0.4, p ¼ 5.6  107; (AA þ AG vs. GG),
OR ¼ 0.3, p ¼ 1.5  107].5 Furthermore, we have examined a total
of 17 SNPs of the near region of TSHZ2 gene using 101 CM-SJS/TEN
cases and 200 control samples, and found that seven SNPs
(rs4811338, rs1555278, rs2092954, rs4371408, rs6021911,
rs4809905, and rs6096940) showed a signiﬁcant genome-wide
association with CM-SJS/TEN with SOCs (Table 2). However, these
SNPswere not associatedwith CM-SJS/TENwith SOCs in the Korean
population (data not shown). TSHZ2 might be a susceptibility gene
for CM-SJS/TEN with SOCs in the Japanese population.
4. Interaction between susceptibility genes
4.1. HLA-A*02:06 and TLR3
SNPs have been widely used as genetic markers for identifying
human disease susceptibility genes for the past decade. Moreover,
it has recently become apparent that geneegene interactions are
meaningful in addition to major single-locus effects.34 We previ-
ously reported that, in addition, HLA-A*02:06,3,11,12 PTGER3,10,34 andGenome-Wide ASI 1 Array. HLA ¼ human leukocyte antigen. Note. From “IKZF1, a new
ecrolysis with severe mucosal involvement,” by M. Ueta, H. Sawai, C. Sotozono C, et al.,
ermission.
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with SOCs, although the expression of TLR3 protein on the ocular
surface was not different between SJS/TEN and controls such as
conjunctival chalasis and chemical burn (Figure 10).34
When we focused on CM-SJS/TEN with SOCs, ﬁve of the seven
SNPs, which were signiﬁcantly associated with SJS/TEN with SOCs
in our previous report,13,34 were still associated with CM-SJS/TEN
with SOCs (Table 3).
We previously also reported that HLA-A*02:06 with TLR3 SNPs
exerted more than additive effects in SJS/TEN with SOCs.13 When
we focused on CM-SJS/TENwith SOCs, more than additive effects of
HLA-A*02:06 with TLR3 SNPs in CM-SJS/TEN with SOCs were still
observed. HLA-A*02:06 and TLR3 SNP rs3775296T/T or TLR3 SNPTable 2
Association between CM-SJS/TEN with SOCs and TSHZ2 gene SNPs.
rs no. of SNP Frequencies of genotypes (%) A
Genotypes Control Case p
O
rs7360046 11 G/G 1/200 (0.5) 0/101 (0.0) 0
12 G/A 27/200 (13.5) 10/101 (9.9) d
22 A/A 172/200 (86.0) 91/101 (90.1) d
rs4811338 11 G/G 29/200 (14.5) 5/101 (5.0) 9
12 G/T 109/200 (54.5) 27/101 (26.7) 0
22 T/T 62/200 (31.0) 69/101 (68.3) (
rs1555278 11 T/T 19/196 (9.7) 5/100 (5.0) 4
12 T/C 96/196 (49.0) 16/100 (16.0) 0
22 C/C 81/196 (41.3) 79/100 (79.0) (
rs6096922 11 G/G 1/200 (0.5) 0/101 (0.0) 0
12 G/A 27/200 (13.5) 10/101 (9.9) d
22 A/A 172/200 (86.0) 91/101 (90.1) d
rs4811342 11 G/G 1/200 (0.5) 0/101 (0.0) 0
12 G/A 27/200 (13.5) 10/101 (9.9) d
22 A/A 172/200 (86.0) 91/101 (90.1) d
rs2092954 11 C/C 29/200 (14.5) 5/101 (5.0) 9
12 C/T 109/200 (54.5) 27/101 (26.7) 0
22 T/T 62/200 (31.0) 69/101 (68.3) (
rs4811343 11 C/C 1/200 (0.5) 0/101 (0.0) 0
12 C/T 21/200 (10.5) 7/101 (6.9) d
22 T/T 178/200 (89.0) 94/101 (93.1) d
rs4371408 11 G/G 29/200 (14.5) 5/101 (5.0) 9
12 G/A 109/200 (54.5) 27/101 (26.7) 0
22 A/A 62/200 (31.0) 69/101 (68.3) (
rs6021911 11 G/G 20/200 (10.0) 5/101 (5.0) 4
12 G/A 98/200 (49.0) 17/101 (16.8) 0
22 A/A 82/200 (41.0) 79/101 (78.2) (
rs4809905 11 A/A 28/200 (14.0) 5/101 (5.0) 6
12 A/G 105/200 (52.5) 24/101 (23.8) 0
22 G/G 67/200 (33.5) 72/101 (71.3) (
rs8123906 11 A/A 3/200 (1.5) 0/101 (0.0) 0
12 A/G 49/200 (24.5) 10/101 (9.9) 0
22 G/G 148/200 (74.0) 91/101 (90.1) (
rs6096940 11 G/G 28/200 (14.0) 5/101 (5.0) 9
12 G/A 104/200 (52.0) 24/101 (23.8) 0
22 A/A 68/200 (34.0) 72/101 (71.3) (
rs968162 11 A/A 20/200 (10.0) 5/101 (5.0) 5
12 A/G 97/200 (48.5) 17/101 (16.8) 0
22 G/G 83/200 (41.5) 79/101 (78.2) (
rs6021974 11 A/A 3/200 (1.5) 0/101 (0.0) 4
12 A/G 49/200 (24.5) 9/101 (8.9) 0
22 G/G 148/200 (74.0) 92/101 (91.1) (
rs1474794 11 T/T 31/200 (15.5) 5/101 (5.0) 1
12 T/C 105/200 (52.5) 34/101 (33.7) 0
22 C/C 64/200 (32.0) 62/101 (61.4) (
rs6068248 11 C/C 30/200 (15.0) 5/100 (5.0) 2
12 C/T 106/200 (53.0) 34/100 (34.0) 0
22 T/T 64/200 (32.0) 61/100 (61.0) (
rs6068268 11 C/C 27/199 (13.6) 33/101 (32.7) 5
12 C/T 97/199 (48.7) 50/101 (49.5) 2
22 T/T 75/199 (37.7) 18/101 (17.8) (
CI ¼ conﬁdence interval; CM-SJS ¼ cold medicine-related StevenseJohnson syndrome
complication; TEN ¼ toxic epidermal necrolysis.
Bold shows the genome wide signiﬁcance (p < 5  10e8).
a p value for allele or genotype frequency comparison between case and control usingrs5743312T/T exerted more than additive effects (p < 0.00005,
OR ¼ 37.7, Woolf's correction or p < 0.00005, OR ¼ 37.5, Woolf's
correction): 10 of 133 patients (7.5%) manifested both HLA-A*02:06
and TLR3 rs3775296T/T SNP or TLR3 rs5743312T/T SNP, whereas
none of the controls did (Table 4). There was a strong linkage
disequilibrium (LD) between rs.3775296 and rs.5743312. Moreover,
HLA-A*02:06 and TLR3 SNP rs3775290A/A exerted additive effects
(p < 0.00005, OR ¼ 9.9): 16 of 133 patients (12.0%) manifested both
HLA-A*02:06 and TLR3 rs3775290A/A SNP, whereas only three of
220 controls (1.4%) did (Table 4).
By interaction analysis, HLA-A*02:06 and TLR3 SNP rs3775296T/
T, which were in strong LDwith TLR3 SNP rs5743312T/T, manifested
more than additive effects; therefore, the multiplicativellele 1 vs. allele 2 Genotype 11 vs. 12 þ 22 Genotype 11 þ 12 vs. 22
a
R (95% CI)
pa
OR (95% CI)
pa
OR (95% CI)
.28 0.48 0.31
d d
d d
.7 £ 10¡9 0.014 7.0  10¡10
.31 0.31 0.21
0.2e0.5) (0.1e0.8) (0.1e0.3)
.0 £ 10¡8 0.16 7.7  10¡10
.29 d 0.19
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; OR ¼ odds ratio; SNP ¼ single nucleotide polymorphism; SOC ¼ severe ocular
the chi-square test.
Figure 10. TLR3 expression in the conjunctival epithelium of SJS/TEN with severe ocular complications. The expression of TLR3 protein (brown stain) on the ocular surface was
not different between SJS/TEN and controls such as conjunctival chalasis and chemical burn. Controls consisted of isotype control antibodies instead of anti-EP3
antibodies. SJS ¼ StevenseJohnson syndrome; TEN ¼ toxic epidermal necrolysis. Note. From “Epistatic interaction between Toll-like receptor 3 (TLR3) and prostaglandin E
receptor 3 (PTGER3) genes,” by M. Ueta, G. Tamiya, K. Tokunaga, et al., 2012, J Allergy Clin Immunol, 129, p. 1413e1416. Copyright 2012, Mosby. Reproduced with permission.
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of CM-SJS/TEN with SOCs.
HLA-A is a component of HLA Class I, which resides on the
surface of all nucleated cells and alerts the immune system that the
cell may be infected by a virus, thereby targeting the cell for
destruction, and TLR3 recognizes viral double-stranded RNA.40
As the onset of SJS/TEN was associated not only with the
administration of drugs but also with putative microbial infection,
multiplicative interactions of HLA-A and TLR3 gene might
contribute to the characteristic and pathogenic immune response
to the microbial infection.
4.2. HLA-A*02:06 and PTGER3
Next, we looked for interactive effects between these seven
SNPs of the PTGER3 gene and HLA-A*02:06 in CM-SJS/TEN withSOCs, because the PTGER3 SNPs were signiﬁcantly associated with
the patients.14 We found an interaction with additive effects be-
tween HLA-A*02:06 and the high-risk genotypes PTGER3
rs1327464 GA or AA (OR ¼ 10.8, p ¼ 2.56  107; Table 5).14 In the
Japanese population, although PTGER3 rs1327464 GA/AA alone
showed OR ¼ 4.48 and p ¼ 1.90  108, and HLA-A*02:06 alone
showed OR¼ 5.46 and p ¼ 1.39  1011, the combination of PTGER3
rs1327464 GA/AA and HLA-A*02:06 could show a higher OR
(OR ¼ 10.8, p ¼ 2.56  107) than each allele alone.
Moreover, we found that even in Korean populations, there was
an additive effect between the SNPs of the PTGER3 gene and HLA-
A*02:06 (Table 6).14 In the Korean population, the combination of
PTGER3 rs1327464 GA/AA and HLA-A*02:06 could show a higher OR
(OR ¼ 14.2, p ¼ 5.58  106) than each allele alone, although
PTGER3 rs1327464 GA/AA alone showed OR¼ 4.07 and p¼ 0.00101,
and HLA-A*02:06 alone showed OR ¼ 2.50 and p ¼ 0.0412.
Table 5
Interaction between HLA-A*02:06 and PTGER3 rs1327464 GA/AA among Japanese individuals.
HLA-A*02:06 rs1327464 GA or AA CM-SJS/TEN with SOC Controls pa OR (95% CI)
þ þ 22/131 (16.8%) 4/218 (1.83%) 2.56  107 10.8 (3.63e32.1)
þ e 39/131 (29.8%) 26/218 (11.9%) 3.38  105 3.13 (1.80e5.45)
e þ 26/131 (19.9%) 21/218 (9.63%) 6.80  103 2.32 (1.25e4.33)
e e 44/131 (33.6%) 167/218 (76.6%) 1.74  1015 0.154 (0.0956e0.249)
CM-SJS ¼ cold medicine-related StevenseJohnson syndrome; HLA ¼ human leukocyte antigen; OR ¼ odds ratio; PTGER3 ¼ prostaglandin E receptor 3; SOC ¼ severe ocular
complication; TEN ¼ toxic epidermal necrolysis.
Note. From “HLA-A*02:06 and PTGER3 polymorphism exerts additive effects in cold medicine-related StevenseJohnson syndrome with severe ocular complications,” by M.
Ueta, K. Tokunaga, C. Sotozono, H. Sawai, K.C. Yoon, M.K. Kim, et al., 2015, Hum Genome Var, 2, p. 15023. Copyright 2015, Nature Publishing Group. Reproduced with permission.
Table 4
Interaction between HLA-A*02:06 and TLR3 SNPs in CM-SJS/TEN with SOCs.
HLA-A*02:06 and TLR3 rs3775296
HLA-A*02:06 rs3775296 感冒薬SJS Controls pa OR (95% CI)
þ þ 10/133 (7.52%) 0/220 (0.00%) 3.69  105 37.6* (2.19e647.7)
þ e 52/133 (39.1%) 30/220 (13.6%) 4.04  108 4.07 (2.42e6.83)
e þ 8/133 (6.02%) 12/220 (5.45%) 0.8253 1.11 (0.441e2.79)
e e 63/133 (47.4%) 178/220 (80.9%) 5.34  1011 0.212 (0.132e0.343)
HLA-A*02:06 and TLR3 rs5743312
HLA-A*02:06 rs5743312 感冒薬SJS Controls pa OR (95% CI)
þ þ 10/133 (7.52%) 0/219 (0.00%) 3.84  105 37.5b (2.18e644.7)
þ e 52/133 (39.1%) 30/219 (13.7%) 4.61  108 4.04 (2.41e6.80)
e þ 7/133 (5.26%) 10/219 (4.57%) 0.7674 1.16 (0.431e3.13)
e e 64/133 (48.1%) 179/219 (81.7%) 3.75  1011 0.207 (0.128e0.336)
HLA-A*02:06 and TLR3 rs3775290
HLA-A*02:06 rs3775290 感冒薬SJS Controls pa OR (95% CI)
þ þ 16/133 (12.0%) 3/220 (1.36%) 1.68  105 9.89 (2.82e34.6)
þ e 46/133 (34.6%) 27/220 (12.3%) 5.28  107 3.78 (2.21e6.48)
e þ 10/133 (7.52%) 22/220 (10.0%) 0.4314 0.732 (0.335e1.60)
e e 61/133 (45.9%) 168/220 (76.4%) 6.00  109 0.262 (0.165e0.416)
CI ¼ conﬁdence interval; CM-SJS ¼ cold medicine-related StevenseJohnson syndrome; OR ¼ odds ratio; SNP ¼ single nucleotide polymorphism; SOC ¼ severe ocular
complication; TEN ¼ toxic epidermal necrolysis.
a p value for allele or genotype frequency comparison between case and control using the chi-square test.
b Woolf's correction.
Table 3
Association with TLR3 SNPs in CM-SJS/TEN with SOC in Japanese individuals.
rs no. of SNP Frequencies of genotypes (%) Allele 1 vs. allele 2 Genotype 11 vs. 12 þ 22 Genotype 11 þ 12 vs. 22
Genotypes Control Case pa
OR (95% CI)
pa
OR (95% CI)
pa
OR (95% CI)
rs4861699 11 A/A 28/221 (12.7) 8/86 (9.3) 0.0156 0.4102 0.0066
12 A/G 105/221 (47.5) 29/86 (33.7) 0.62 0.71 0.50
22 G/G 88/221 (39.8) 49/86 (57.0) (0.4e0.9) (0.3e1.6) (0.3e0.8)
rs6822014 11 G/G 9/214 (4.2) 13/131 (9.9) 0.0673 0.0349 0.2377
12 G/A 72/214 (33.6) 45/131 (34.4) 1.40 2.51 1.30
22 A/A 133/214 (62.1) 73/131 (55.7) (1.0e2.0) (1.0e6.0) (0.8e2.0)
rs11732384 11 A/A 16/220 (7.3) 9/133 (6.8) 0.1737 0.8575 0.1081
12 A/G 91/220 (41.4) 44/133 (33.1) 0.78 0.93 0.70
22 G/G 113/220 (51.4) 80/133 (60.2) (0.6e1.1) (0.4e2.2) (0.5e1.1)
rs3775296 11 T/T 12/220 (5.5) 18/133 (13.5) 0.0604 0.0083 0.3436
12 T/G 94/220 (42.7) 53/133 (39.8) 1.37 2.71 1.23
22 G/G 114/220 (51.8) 62/133 (46.6) (1.0e1.9) (1.3e5.8) (0.8e1.9)
rs5743312 11 T/T 10/219 (4.6) 17/133 (12.8) 0.0492 0.0050 0.3195
12 T/C 90/219 (41.1) 51/133 (38.3) 1.40 3.06 1.24
22 C/C 119/219 (54.3) 65/133 (48.9) (1.0e2.0) (1.4e6.9) (0.8e1.9)
rs7668666 11 A/A 27/212 (12.7) 26/133 (19.5) 0.0986 0.0876 0.2795
12 A/C 101/212 (47.6) 62/133 (46.6) 1.30 1.66 1.28
22 C/C 84/212 (39.6) 45/133 (33.8) (1.0e1.8) (0.9e3.0) (0.8e2.0)
rs3775290 11 A/A 25/220 (11.4) 26/133 (19.5) 0.1554 0.0340 0.6324
12 A/G 110/220 (50.0) 59/133 (44.4) 1.25 1.90 1.11
22 G/G 85/220 (38.6) 48/133 (36.1) (0.9e1.7) (1.0e3.4) (0.7e1.7)
CI ¼ conﬁdence interval; CM-SJS ¼ cold medicine-related StevenseJohnson syndrome; OR ¼ odds ratio; SNP ¼ single nucleotide polymorphism; SOC ¼ severe ocular
complication; TEN ¼ toxic epidermal necrolysis.
Bold shows p < 0.05.
a p value for allele or genotype frequency comparison between case and control using the chi-square test.
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Table 6
Interaction between HLA-A*02:06 and PTGER3 rs1327464 GA/AA among Korean individuals.
HLA-A*02:06 rs1327464 GA or AA CM-SJS/TEN with SOC Controls pa OR (95% CI)
þ þ 8/30 (26.7%) 3/120 (2.50%) 5.58  106 14.2 (3.49e57.7)
þ e 2/30 (6.67%) 17/120 (14.2%) 0.269 0.433 (0.0943e1.99)
e þ 5/30 (16.7%) 16/120 (13.3%) 0.638 1.30 (0.435e3.89)
e e 15/15 (50.0%) 84/120 (70.0%) 0.0386 0.429 (0.190e0.968)
CM-SJS ¼ cold medicine-related StevenseJohnson syndrome; HLA ¼ human leukocyte antigen; OR ¼ odds ratio; PTGER3 ¼ prostaglandin E receptor 3; SOC ¼ severe ocular
complication; TEN ¼ toxic epidermal necrolysis.
Note. From “HLA-A*02:06 and PTGER3 polymorphism exerts additive effects in cold medicine-related StevenseJohnson syndrome with severe ocular complications,” by M.
Ueta, K. Tokunaga, C. Sotozono, H. Sawai, K.C. Yoon, M.K. Kim, et al., 2015,Hum Genome Var, 2, p. 15023. Copyright 2015, Nature Publishing Group. Reproduced with permission.
a p value for allele or genotype frequency. Comparison was between patients and controls using the chi-square test (Pearson).
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might strongly contribute to the onset of CM-SJS/TEN with SOCs.
5. Application strategy in future
Because CM-SJS/TEN is a rare condition that probably has a
complex genetic background, it is reasonable to posit multiplicative
interactions of genes such as HLA-A and TLR3,13 and HLA-A and
PTGER3.14
Notably, after removing samples with both HLA-A*02:06 and
TLR3 SNP rs3775296 T/T, the additive effect between HLA-A*02:06
and PTGER3 rs1327464 GA/AA persisted in CM-SJS/TEN with SOCs,
suggesting that the interactions are independent of each other.14
These ﬁndings might show that the combinations of the two
CM-SJS/TEN with SOCs associated polymorphisms, such as HLA-
A*02:06 and TLR3 SNP and HLA-A*02:06 and PTGER3 SNP, could give
improvements for a genetic testing compared with using only one
susceptibility gene.14
Based on all of our previous observations, we suggest that in
addition to microbial infections and cold medicines, the combina-
tion of multiple gene polymorphisms and their interactions
contribute strongly to the onset of CM-SJS/TEN with SOCs.14
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